IP Library › Granted Patent US 7,863,298

Granted Patent B2

US 7,863,298 · App. 10/576,228 · Granted Jan 4, 2011

Bridged ring structures as pharmaceutical agents

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,863,298
App. No.: 10/576,228
Granted: Jan 4, 2011
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention is directed to 1α,25-dihydroxyvitamin D3 mimics which modulate the vitamin D receptor (VDR). The invention is further directed to pharmaceutical compositions and methods for the treatment, prevention or amelioration of one or more symptoms of disease or disorder related to the activity of the vitamin D receptor using an effective amount of a compound of formula (I).

Claims (220)

1. A compound having the formula (I):

wherein:

R 1 and R 2 are each independently halo, haloalkyl, cyanido, cyanato, thiocyanato, selenocyananto, trifluoromethoxy, azido, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, or optionally substituted heteroaryl; or

R 1 and R 2 , together with the carbon atom to which they are attached, form an optionally substituted heterocyclyl selected from a group consisting of:

wherein A is —O—, —NR x —, —S—, —S(O)— or —S(O) 2 — wherein R x is hydrogen, alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —R 14 —C(J)R 15 , —R 14 —C(J)OR 15 , —R 14 —C(J)R 16 OR 15 , —R 14 —C(J)SR 16 , —R 14 —C(J)N(R 18 )R 19 , —R 14 —C(J)N(R 17 )N(R 18 )R 19 , —R 14 —C(J)N(R 17 )S(O) p R 20 , —R 14 —S(O) p N(R 18 )R 19 or —R 14 —S(O) p R 20 ; and wherein B is —O—, —S— or —NR y — wherein R y is hydrogen, alkyl, haloalkyl, aryl or heteroaryl; and wherein each p is independently 0 to 2;

R 3 and R 4 are each independently alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl, halo, cyanido, cyanato, thiocyanato, selenocyanato, trifluoromethoxy, azido, haloalkyl, nitro, cyano, azido, —R 14 —R 15 , —R 14 —N(R 18 )R 19 —R 14 —SR 15 , —R 14 —OC(J)R 15 , —R 14 —NR 17 C(J)R 15 , —R 14 —OC(J)N(R 18 )R 19 , —R 14 —NR 17 C(J)N(R 18 )R 19 , —R 14 —NR 17 C(J)OR 15 , —R 14 —C(J)R 15 , —R 14 —C(J)OR 15 , —R 14 —C(J)SR 16 , —R 14 —C(J)N(R 18 )R 19 or —R 14 C(J)N(R 17 )N(R 18 )R 19 ;

R 5 , R 6 , R 7 , R 8 , R 9 , R 10 are each independently hydrogen, amino, cyanido, cyanato, thiocyanato, selenocyanato, trifluoromethoxy, azido, cyano, nitro, alkyl, haloalkyl, alkoxy or haloalkoxy;

X is R 25 ;

Y is independently R 30 , —OR 31 , —SR 32 or —N(R 33 )(R 34 );

R 25 and R 30 are each independently selected from (i) or (ii) as follows:

(i) optionally substituted alkyl that may be substituted with one to ten substituents each independently selected from a group consisting of halo, cyanido, cyanato, thiocyanato, selenocyanato, trifluoromethoxy, azido, nitro, cyano, thioxo, azido, amidino, guanidino, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, —OR 15 , —OR 16 OR 15 , —N(R 18 )R 19 , —N(R 17 )N(R 18 )R 19 , —SR 15 , —SR 16 SR 15 , —N(R 17 )N(R 17 )S(O) p R 20 , —OC(J)R 15 , —NR 17 C(J)R 15 , —OC(J)N(R 18 )R 19 , —NR 17 C(J)N(R 18 )R 19 , —NR 17 C(J)OR 15 , —OC(J)OR 15 , —P(R 21 ) 2 , —P(O)(R 21 ) 2 , —OP(O)(R 21 ) 2 , —C(J)R 15 , —C(J)OR 15 , —C(J)SR 16 , —C(J)N(R 18 )R 19 , —C(J)N(R 17 )N(R 18 )R 19 , —C(J)N(R 17 )N(R 17 )S(O) p R 20 , —C(R 17 )═NOR 15 , —C(R 17 )═NR 17 , —C(R 17 )═NN(R 18 )R 19 and —C(═NR 17 )N(R 18 )R 19 ; or

(ii) optionally substituted alkenyl or optionally substituted alkynyl, either of which may be substituted with one to ten substituents each independently selected from a group consisting of oxo, thioxo, halo, cyanido, cyanato, thiocyanato, selenocyanato, trifluoromethoxy, azido, nitro, cyano, azido, amidino, guanidino, —OR 15 , —OR 16 OR 15 , —N(R 18 )R 19 , —N(R 17 )N(R 18 )R 19 , —SR 15 , —SR 16 SR 15 , —S(O) p R 20 , —N(R 17 )S(O) p R 20 ,-N(R 17 )N(R 17 )S(O) p R 20 , —OC(J)R 15 , —NR 17 C(J)R 15 , —OC(J)N(R 18 )R 19 , —NR 17 C(J)N(R 18 )R 19 , —NR 17 C(J)OR 15 , —OC(J)OR 15 , —P(R 21 ) 2 , —P(O)(R 21 ) 2 , —OP(O)(R 21 ) 2 , —C(J)R 15 , —C(J)OR 15 , —C(J)SR 16 , —C(J)N(R 18 )R 19 , —C(J)N(R 17 )N(R 18 )R 19 , —C(J)N(R 17 )S(O) p R 20 , —C(J)N(R 17 )N(R 17 )S(O) p R 20 , —C(R 17 )═NOR 15 , —C(R 17 )═NR 17 , —C(R 17 )═NN(R 18 )R 19 , —C(═NR 17 )N(R 18 )R 19 , alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;

R 31 , R 32 , R 33 and R 34 are each independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted cycloalkyl; all of which, when substituted, are substituted with one to ten substituents each independently selected from a group consisting of oxo, halo, cyanido, cyanato, thiocyanato, selenocyanato, trifluoromethoxy, azido, nitro, cyano, azido, amidino, guanidino, —OR 15 , —OR 16 OR 15 , —N(R 18 )R 19 , —N(R 17 )N(R 18 )R 19 , —SR 15 , —SR 16 SR 15 , —S(O) p R 20 , —N(R 17 )S(O) p R 20 , —N(R 17 )N(R 17 )S(O) p R 20 , —OC(J)R 15 , —NR 17 C(J)R 15 , —OC(J)N(R 18 )R 19 , —NR 17 C(J)N(R 18 )R 19 , —NR 17 C(J)OR 15 , —OC(J)OR 15 , —P(R 21 ) 2 , —P(O)(R 21 ) 2 , —OP(O)R 21 ) 2 , —C(J)R 15 , —C(J)OR 15 , —C(J)SR 16 , —C(J)N(R 18 )R 19 , —C(J)N(R 17 )N(R 18 )R 19 , —C(J)N(R 17 )S(O) p R 20 , —C(J)N(R 17 )N(R 17 )S(O) p R 20 , —C(R 17 )═NOR 15 , —C(R 17 )═NR 17 , —C(R 17 )═NN(R 18 )R 19 , —C(═NR 17 )N(R 18 )R 19 , alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, and R 34 can additionally be hydrogen;

where each R 14 is independently a direct bond or alkylene;

where each R 15 and R 17 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl, all of which, when substituted, are substituted with one to five substituents each independently selected from halo, cyano, hydroxy and amino;

where each R 16 and R 20 is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl, all of which, when substituted, are substituted with one to five substituents each independently selected from halo, hydroxy, alkoxy and amino; and

where each R 18 and R 19 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl, all of which, when substituted, are substituted with one to five substituents each independently selected from halo, hydroxy, alkoxy and amino;

or where R 18 and R 19 , together with the nitrogen atom to which they are attached, form a heterocyclyl or heteroaryl;

each R 21 is independently alkyl, —OR 22 or —N(R 23 )R 24 ;

R 22 is hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or aralkyl;

R 23 and R 24 are each independently hydrogen, alkyl, haloalkyl, alkenyl, alkynyl or cycloalkyl;

or R 23 and R 24 , together with the nitrogen atom to which they are attached, form a heterocyclyl or heteroaryl;

each J is independently O or S;

as a single isomer, a mixture of isomers, or as a racemic mixture of isomers; as a solvate or polymorph; or as a prodrug or metabolite; or as a pharmaceutically acceptable salt thereof;

provided that when R 1 and R 2 form a substituted cyclohexyl, said cyclohexyl, when substituted at the 4-position relative to the gem-diaryl substituents, is substituted with a substituent selected from the group consisting of halo, cyano, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl and optionally substituted heteroaryl; and

provided that neither R 25 nor R 30 is:

—CH 2 COOH;

—CH 2 -5-tetrazolyl;

—CH 2 COOMe;

—CH 2 COOEt;

—CH 2 NH(CH 2 COOH);

—CH 2 N(C(O)Me)(CH 2 COOH);

—CH 2 —N-pyrrolidin-2-one;

—CH 2 -(1-methylpyrrolidin-2-one-3-yl);

—CH 2 COOH;

—CH 2 C(O)NH 2 ;

—CH 2 C(O)NMe 2 ;

—CH 2 C(O)NHMe;

—CH 2 C(O)—N-pyrrolidine;

—CH(OH)COOH;

—CH(OH)C(O)NH 2 ;

—CH(OH)C(O)NHMe;

—CH(OH)C(O)NMe 2 ;

—CH(OH)C(O)NEt 2 ;

—CH 2 CH 2 COOH;

—CH 2 CH 2 COOMe;

—CH 2 CH 2 COOEt;

—CH 2 CH 2 COOMe;

—CH 2 CH 2 COOEt;

—CH 2 CH 2 C(O)NH 2 ;

—CH 2 CH 2 C(O)NHMe;

—CH 2 CH 2 C(O)NMe 2 ; or

—CH 2 CH 2 -5-tetrazolyl.

2. The compound of claim 1 wherein:

R 1 and R 2 are each independently halo, haloalkyl, cyanido, cyanato, thiocyanato, selenocyanato, trifluoromethoxy, azido, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, or optionally substituted heteroaryl; or

R 1 and R 2 , together with the carbon atom to which they are attached, form an optionally substituted heterocyclyl selected from a group consisting of:

R 25 and R 30 are each independently selected from (i), (ii) or (iii) as follows:

(i) optionally substituted alkyl that may be substituted with one to ten substituents each independently selected from a group consisting of halo, cyanido, cyanato, thiocyanato, selenocyanato, trifluoromethoxy, azido, nitro, cyano, thioxo, azido, amidino, guanidino, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, —OR 15 , —OR 16 OR 15 , —N(R 18 )R 19 , —N(R 17 )N(R 18 )R 19 , —SR 15 , —SR 16 SR 15 , —N(R 17 )N(R 17 )S(O) p R 20 , —OC(J)R 15 , —NR 17 C(J)R 15 , —OC(J)N(R 18 )R 19 , —NR 17 C(J)N(R 18 )R 19 , —NR 17 C(J)OR 15 , —OC(J)OR 15 , —P(R 21 ) 2 , —P(O)(R 21 ) 2 , —OP(O)(R 21 ) 2 , —C(J)R 15 , —C(J)SR 16 , —C(J)N(R 17 )N(R 18 )R 19 , —C(J)N(R 17 )N(R 17 )S(O) p R 20 , —C(R 17 )═NOR 15 , —C(R 17 )═NR 17 , —C(R 17 )═NN(R 18 )R 19 and —C(═NR 17 )N(R 18 )R 19 ;

(ii) substituted propyl, substituted butyl or substituted pentyl, wherein said optionally substituted propyl, said optionally substituted butyl or said optionally substituted pentyl can additionally be substituted with substituents selected from the group consisting of —C(J)OR 15 , —C(J)N(R 18 )R 19 and optionally substituted heteroaryl; or

(iii) optionally substituted alkenyl or optionally substituted alkynyl, either of which may be substituted with one to ten substituents each independently selected from a group consisting of oxo, thioxo, halo, cyanido, cyanato, thiocyanato, selenocyanato, trifluoromethoxy, azido, nitro, cyano, azido, amidino, guanidino, —OR 15 , —OR 16 OR 15 , —N(R 18 )R 19 , —N(R 17 )N(R 18 )R 19 , —SR 15 , —SR 16 SR 15 , —S(O) p R 20 , —N(R 17 )S(O) p R 20 , —N(R 17 )N(R 17 )S(O) p R 20 , —OC(J)R 15 , —NR 17 C(J)R 15 , —OC(J)N(R 18 )R 19 , —NR 17 C(J)N( 18 )R 19 , —NR 17 C(J)OR 15 , —OC(J)OR 15 , —P(R 21 ) 2 , —P(O)(R 21 ) 2 , —OP(O)(R 21 ) 2 , —C(J)R 15 , —C(J)OR 15 , —C(J)SR 16 , —C(J)N(R 18 )R 19 , —C(J)N(R 17 )N(R 18 )R 19 , —C(J)N(R 17 )S(O) p R 20 , —C(J)N(R 17 )N(R 17 )S(O) p R 20 , —C(R 17 )═NOR 15 , —C(R 17 )═NR 17 , —C(R 17 )═NN(R 18 )R 19 , —C(═NR 17 )N(R 18 )R 19 , alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;

where R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 are as described in claim 1 .

3. The compound of claim 2 wherein R 25 , R 30 , R 31 , R 32 , R 33 and R 34 are Each independently optionally substituted alkyl selected from group a) or group b), optionally substituted alkenyl selected from group c) or group d) or optionally substituted alkynyl selected from group e) or group f);

wherein R 31 , R 32 , R 33 and R 34 can additionally be optionally substituted cycloalkyl selected from group g);

and wherein R 34 can additionally be hydrogen;

wherein group (a) consists of:

wherein group (b) consists of:

wherein group (c) consists of both cis and trans conformations of:

and group (d) consists of both cis and trans conformations of:

wherein group (e) consists of:

wherein group (f) consists of:

and wherein group (g) consists of:

wherein each Z is independently OH, OR, NH 2 , NHR, N(R)(R) wherein R is each independently alkyl or haloalkyl; each n is independently an integer from 0 to 4; each m is independently an integer from 1 to 2 and each q is independently an integer from 0 to 4;

and wherein any member of groups a), b) c), d), e), f) and g) may optionally be halogenated.

4. The compound of claim 3 wherein:

X is R 25 ;

Y is —SR 32 or —N(R 33 )(R 34 );

R 1 and R 2 are each independently alkyl or haloalkyl;

R 3 and R 4 are each independently , halo, cyanido, cyanato, thiocyanato, selenocyanato, trifluoromethoxy, azido, alkyl or haloalkyl;

R 5 , R 6 , R 7 , R 8 , R 9 , R 10 are hydrogen; and

R 25 , R 32 , R 33 and R 34 are as described in claim 3 .

5. The compound of claim 3 wherein:

X is R 25 ;

Y is —OR 31 ;

R 1 and R 2 are each independently alkyl or haloalkyl;

R 3 and R 4 are each independently halo, cyanido, cyanato, thiocyanato, selenocyanato, trifluoromethoxy, azido, alkyl or haloalkyl;

R 5 , R 6 , R 7 , R 8 , R 9 , R 10 are hydrogen; and

R 25 and R 31 are as described in claim 3 .

6. The compound of claim 5 wherein R 25 is optionally substituted alkyl Selected from group (a) and R 31 is optionally substituted alkyl selected from group (b).

7. The compound of claim 6 wherein R 3 and R 4 are each independently halo, alkyl or haloalkyl.

8. The compound of claim 7 wherein the compounds are selected from a group consisting of:

3-(4-{1-ethyl-1-[4-(3-hydroxy-3-methylbutyl)-3-methylphenyl]-propyl}-2-methylphenoxy)-propane-1,2(S)-diol;

3-(4-{1-ethyl-1-[4-(3-ethyl-3-hydroxypentyl)-3-methylphenyl]-propyl}-2-methyl-phenoxy)-propane-1,2(S)-diol;

3-(4-{1-ethyl-1-[4-(3-hydroxy-5-methylhexyl)-3-methylphenyl]-propyl}-2-methyl-phenoxy)-propane-1,2(S)-diol;

3-(4-{1-ethyl-1-[4-(3-hydroxy-4-methylpentyl)-3-methylphenyl]-propyl}-2-methyl-phenoxy)-propane-1,2(S)-diol;

3-(2-ethyl-4-{1-ethyl-1-[4-(3-hydroxy-4,4-dimethylpentyl)-3-methylphenyl]-propyl}-phenoxy)-propane-1,2(S)-diol;

3-(4-{1-ethyl-1-[4-(3-hydroxy-4,4-dimethylpentyl)-3-methylphenyl]-propyl}-2-methyl-phenoxy)-propane-1,2(S)-diol;

3-[4-(1-ethyl-1-{4-[3(S)-hydroxy-4,4-dimethylpentyl]-3-methylphenyl}-propyl) 2-methyl-phenoxy]-propane-1,2(S)-diol; and

3-[4-(1-ethyl-1-{4-[3(R)-hydroxy-4,4-dimethylpentyl]-3-methylphenyl}-propyl) 2-methyl-phenoxy]-propane-1,2(S)-diol.

9. The compound of claim 6 wherein R 3 is halo and R 4 is alkyl, halo or haloalkyl.

10. The compound of claim 6 wherein R 3 is alkyl, halo or haloalkyl and R 4 is halo.

11. The compound of claim 5 wherein R 25 is optionally substituted alkenyl selected from group (c) or group (d) and R 31 is optionally substituted alkyl selected from group (a) or group (b).

12. The compound of claim 11 wherein R 3 and R 4 are each independently alkyl or haloalkyl.

13. The compound of claim 12 , selected from the group consisting of:

(Z)-3-(4-{1-ethyl-1-[4-(3-hydroxy-4,4-dimethylpent-1-enyl) -3-methylphenyl]-propyl}-2-methylphenoxy)-propane-1,2(S)-diol;

(E)-3-(4-{1-ethyl-1-[4-(3-hydroxy-4,4-dimethylpent-1-enyl)-3-methylphenyl]-propyl}-2-methylphenoxy)-propane-1,2(S)-diol; and

(E)-3-(4-{1-ethyl-1-[4-(3-ethyl-3-hydroxypent-1-enyl)-3-methylphenyl]-propyl}-2-methylphenoxy)-propane-1,2(S)-diol.

14. The compound of claim 11 wherein R 3 is alkyl or haloalkyl and R 4 is halo.

15. The compound of claim 5 wherein R 25 is optionally substituted alkynyl selected from group (e) or group (f) and R 31 is optionally substituted alkyl selected from group (a) or group (b).

16. The compound of claim 15 wherein R 3 and R 4 are each independently alkyl or haloalkyl.

17. The compound of claim 16 selected from the group consisting of

3-(4-{1-ethyl-1-[4-(3-hydroxy-4,4-dimethylpent-1-ynyl)-3-methylphenyl]-propyl}-2-methylphenoxy)-propane-1,2(S)-diol;

3-(4-{1-ethyl-1-[4-(3(R)-hydroxy-4,4-dimethylpent-1-ynyl)-3-methylphenyl]-propyl}-2-methylphenoxy)-propane-1,2(S)-diol;

3-(4-{1-ethyl-1-[4-(3(S)-hydroxy-4,4-dimethylpent-1-ynyl)-3-methylphenyl]-propyl}-2-methylphenoxy)-propane-1,2(S)-diol; and

3-(4-{1-ethyl-1-[4-(3-ethyl-3-hydroxypent-1-ynyl)-3-methyl-phenyl]-propyl}-2-methylphenoxy)-propane-1,2(S)-diol.

18. The compound of claim 1 wherein:

X is R 25 ;

Y is R 30 ; and

R 25 and R 30 are as described in claim 1 .

19. The compound of claim 18 wherein:

R 1 and R 2 are each independently optionally substituted alkyl or haloalkyl;

R 3 and R 4 are each independently halo, cyanido, cyanato, thiocyanato, selenocyanato, trifluoromethoxy, azido, alkyl or haloalkyl;

R 5 , R 6 , R 7 , R 8 , R 9 , R 10 are hydrogen;

R 25 and R 30 are each independently substituted alkyl selected from group a) or group b), substituted alkenyl selected from group c) or group d) or substituted alkynyl selected from group e) or group f);

wherein group (a) consists of:

wherein group (b) consists of:

wherein group (c) consists of both cis and trans conformations of:

wherein group (d) consists of both cis and trans conformations of:

wherein group (e) consists of:

wherein group (f) consists of:

wherein each Z is independently OH, OR, NH 2 , NHR, N(R)(R) wherein R is independently alkyl or haloalkyl; each n is independently an integer from 0 to 4; each m is independently an integer from 1 to 2 and each q is independently an integer from 0 to 4;

and wherein any member of groups a), b) c), d), e), f) and g) may optionally be halogenated.

20. The compound of claim 19 wherein R 25 is optionally substituted alkyl selected from group a), optionally substituted alkenyl selected from group c) or optionally substituted alkynyl selected from group e) and R 30 is optionally substituted alkyl selected from group b).

21. The compound of claim 20 wherein R 3 and R 4 are each independently alkyl or haloalkyl.

22. The compound of claim 20 wherein R 3 is alkyl or haloalkyl and R 4 is hydrogen.

23. The compound of claim 1 wherein

X is R 25 ;

Y is —OR 31 ;

R 1 and R 2 are ethyl;

R 3 and R 4 are methyl;

R 25 is selected from the group consisting of:

R 31 is selected from the group consisting of:

wherein each Z is independently OH, OR, NH 2 , NHR, N(R)(R) wherein R is independently alkyl or haloalkyl; each n is independently an integer from 0 to 4 and each m is independently an integer from 1 to 2.

24. The compound of claim 1 wherein:

X is R 25 ;

Y is —OR 31 ;

R 1 and R 2 are ethyl;

R 3 and R 4 are methyl;

R 25 is selected from the group consisting of both cis and trans conformations of:

R 31 is selected from the group consisting of both cis and trans conformations of:

25. The compound of claim 1 wherein:

X is R 25 ;

Y is —OR 31 ;

R 1 and R 2 are ethyl;

R 3 and R 4 are methyl;

R 25 is selected from the group consisting of:

R 31 is selected from the group consisting of:

26. A pharmaceutical composition comprising a compound of claim 1 and one or more additional ingredient selected from the group consisting of an anticancer agent, an anti-autoimmune agent, a parathyroid hormone, a calcium supplement, an anti-arthritic compound, an anti-inflammatory compound, a matrix metalloproteinase inhibitor, an inhibitor of pro-inflammatory cytokines, an NSAID, a corticosteroid, a COX-1 inhibitor, a COX-2 inhibitor, acetaminophen and ibuprofen.

27. A method of supplementing treatment of a disease or disorder selected from the group consisting of hyperparathyroidism, renal failure, osteomalacia, intestinal malabsorption syndrome, osteoporosis, Alzheimers disease, hyperproliferative skin diseases, psoriasis, pruritis, acne and seborrheic dermatitis, comprising administering to a subject in need thereof an effective amount of a compound of claim 1 .

28. A method of supplementing treatment of breast cancer colon cancer, prostate cancer, ovarian cancer, brain glial tumors, squamous cell carcinoma, ovarian cancer, myeloid leukemia, osteosarcoma; myelofibrosis and melanoma, comprising administering to a subject in need thereof an effective amount of a compound of claim 1 .

29. The method of claim 28 wherein said method further comprises administering one additional active ingredient selected from a group comprising 5-fluoro-uracil, methotrexate, fludarabine, antimicrotubule agents, vincristine, vinblastine, taxanes, paclitaxel, docetaxel, alkylating agent, cyclophasphamide, melphalan, biochoroethylnitrosurea, hydroxyurea, platinum agents, cisplatin, carboplatin, oxaliplatin, JM-216, Cl-973, anthracyclines, doxrubicin, daunorubicin, antibiotics, mitomycin, idarubicin, adriamycin, daunomycin), topoisomerase inhibitiors, etoposide, camptothecins, or any other cytotoxic agents, estramustine phosphate, prednimustine, steroids, anti-steroids, estrogens, anti-estrogens, androgens, anti-androgens, glucocorticoids and dexamethasone.

30. The method of claim 29 wherein said method further comprises the administration in conjunction with chemotherapy or radiation therapy of a compound of formula (I)

wherein:

R 1 and R 2 , together with the carbon atom to which they are attached, form an optionally substituted heterocyclyl selected from a group consisting of:

R 3 and R 4 are each independently alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyanido, cyanato, thiocyanato, selenocyanato, trifluoromethoxy, azido, haloalkyl, nitro, cyano, azido, —R 14 -R 15 , —R 14 —N(R 18 )R 19 , —R 14 —SR 15 , —R 14 —OC(J)R 15 , —R 14 —NR 17 C(J)R 15 , —R 14 —OC(J)N(R 18 )R 19 , —R 14 —NR 17 C(J)N(R 18 )R 19 , —R 14 —NR 17 C(J)OR 15 , —R 14 —C(J)R 15 , —R 14 —C(J)OR 15 , —R 14 —C(J)SR 16 , —R 14 —C(J)N(R 18 )R 19 or —R 14 C(J)N(R 17 )N(R 18 )R 19 ;

R 5 , R 6 , R 7 , R 8 , R 9 , R 10 are each independently hydrogen, amino, cyanido, cyanato, thiocyanato, selenocyanato, trifluoromethoxy, azido, cyano, nitro, alkyl, haloalkyl, alkoxy or haloalkoxy;

X is R 25 ;

Y is independently R 30 , —OR 31 , —SR 32 or —N(R 33 )(R 34 );

R 25 and R 30 are each independently selected from (i) or (ii) as follows:

(i) optionally substituted alkyl that may be substituted with one to ten substituents each independently selected from a group consisting of halo, cyanido, cyanato, thiocyanato, selenocyanato, trifluoromethoxy, azido, nitro, cyano, thioxo, azido, amidino, guanidino, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, —OR 15 , —OR 16 OR 15 , —N(R 18 OR 19 , —N(R 17 )N(R 18 )R 19 , —SR 15 , —SR 16 SR 15 , —N(R 17 )N(R 17 )S(O) p R 20 , —OC(J)R 15 , —NR 17 C(J)R 15 , —OC(J)N(R 18 )R 19 ; —NR 17 C(J)N(R 18 )R 19 , —NR 17 C(J)OR 15 , —OC(J)OR 15 , —P(R 21 ) 2 , —P(O)(R 21 ) 2 , —OP(O)(R 21 ) 2 , —C(J)R 15 , —C(J)OR 15 , —C(J)SR 16 , —C(J)N(R 18 )R 19 , —C(J)N(R 17 )N(R 18 )R 19 , —C(J)N(R 17 )N(R 17 )S(O) p R 20 , —C(R 17 )═NOR 15 , —C(R 17 )═NR 17 , —C(R 17 )═NN(R 18 )R 19 and —C(═NR 17 )N(R 18 )R 19 ; or

(ii) optionally substituted alkenyl or optionally substituted alkynyl, either of which may be substituted with one to ten substituents each independently selected from a group consisting of oxo, thioxo, halo, cyanido, cyanato, thiocyanato, selenocyanato, trifluoromethoxy, azido, nitro, cyano, azido, amidino, guanidino, —OR 15 , —OR 16 OR 15 , —N(R 18 )R 19 , —N(R 17 )N(R 18 )R 19 , —SR 15 , —SR 16 SR 15 , —S(O) p R 20 , —N(R 17 )S(O) p R 20 , —N(R 17 )N(R 17 )S(O) p R 20 , —OC(J)R 15 , —NR 17 C(J)R 15 , —OC(J)N(R 18 )R 19 , —NR 17 C(J)N(R 18 )R 19 , —NR 17 C(J)OR 15 , —OC(J)OR 15 , —P(R 21 ) 2 , —P(O)(R 21 ) 2 , —OP(O)(R 21 ) 2 , —C(J)R 15 , —C(J)OR 15 , —C(J)SR 16 , —C(J)N(R 18 )R 19 , —C(J)N(R 17 )N(R 18 )R 19 , —C(J)N(R 17 )S(O) p R 20 , —C(J)N(R 17 )N(R 17 )S(O)R 20 , —C(R 17 )═NOR 15 , —C(R 17 )═NR 17 , —C(R 17 )═NN(R 18 )R 19 , —C(═NR 17 )N(R 18 )R 19 , alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;

R 31 , R 32 , R 33 and R 34 are each independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted cycloalkyl: all of which, when substituted, are substituted with one to ten substituents each independently selected from a group consisting of oxo, halo, cyanido, cyanato, thiocyanato, selenocyanato, trifluoromethoxy, azido, nitro, cyano, azido, amidino, guanidino, —OR 15 , —OR 16 OR 15 , —N(R 18 )R 19 , —N(R 17 )N(R 18 )R 19 , —SR 15 , —SR 16 SR 15 , —S(O) p R 20 , —N(R 17 )S(O) p R 20 , —N(R 17 )N(R 17 )S(O) p R 20 , —OC(J)R 15 , —NR 17 C(J)R 15 , —OC(J)N(R 18 )R 19 , —NR 17 C(J)N(R 18 )R 19 , —NR 17 C(J)OR 15 , —OC(J)OR 15 , —P(R 21 ) 2 , —P(O)(R 21 ) 2 , —OP(O)(R 21 ) 2 , —C(J)R 15 , —C(J)OR 15 , —C(J)SR 16 , —C(J)N(R 18 )R 19 , —C(J)N(R 17 )N(R 18 )R 19 , —C(J)N(R 17 )S(O) p R 20 , —C(J)N(R 17 )N(R 17 )S(O) p R 20 , —C(R 17 )═NOR 15 , —C(R 17 )═NR 17 , —C(R 17 )═NN(R 18 )R 19 , —C(═NR 17 )N(R 18 )R 19 , alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, and R 34 can additionally be hydrogen:

where each R 14 is independently a direct bond or alkylene;

or where R 18 and R 19 , together with the nitrogen atom to which they are attached, form a heterocyclyl or heteroaryl;

each R 21 is independently alkyl, —OR 22 or —N(R 23 )R 24 ;

R 22 is hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or aralkyl;

R 23 and R 24 are each independently hydrogen, alkyl, haloalkyl, alkenyl, alkynyl or cycloalkyl;

or R 23 and R 24 , together with the nitrogen atom to which they are attached, form a heterocyclyl or heteroaryl;

each J is independently O or S:

as a single isomer, a mixture of isomers, or as a racemic mixture of isomers; as a solvate or polymorph; or as a prodrug or metabolite: or as a pharmaceutically acceptable salt thereof;

provided that neither R 25 nor R 30 is:

—CH 2 COOH;

—CH 2 -5-tetrazolyl;

—CH 2 COOMe;

—CH 2 COOEt;

—CH 2 NH(CH 2 COOH);

—CH 2 N(C(O)Me)(CH 2 COOH);

—CH 2 -N-pyrrolidin-2-one;

—CH 2 -(1-methylpyrrolidin-2-one-3-yl);

—CH 2 COOH;

—CH 2 C(O)NH 2 ;

—CH 2 C(O)NMe 2 ;

—CH 2 C(O)NHMe;

—CH 2 C(O)—N-pyrrolidine;

—CH(OH)COOH;

—CH(OH)C(O)NH 2 ;

—CH(OH)C(O)NHMe;

—CH(OH)C(O)NMe 2 ;

—CH(OH)C(O)NEt 2 ;

—CH 2 CH 2 COOH;

—CH 2 CH 2 COOMe;

—CH 2 CH 2 COOEt;

—CH 2 CH 2 COOMe;

—CH 2 CH 2 COOEt;

—CH 2 CH 2 C(O)NH 2 ;

—CH 2 CH 2 C(O)NHMe;

—CH 2 CH 2 C(O)NMe 2 ; or

—CH 2 CH 2 -5-tetrazolyl.

31. A compound which is:

3-(4-{1-ethyl-1-[4-(3-hydroxy-4,4-dimethylpentyl)-phenyl]-propyl}-2-methylphenoxy)-propane-1,2(S)-diol; or

3-(4-{1-ethyl-1-[4-(3-hydroxy-4,4-dimethyl-pentyl) -3-methyl-phenyl]-propyl}-phenoxy)-propane-1,2(S)-diol.

Assignments (1)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2006

From: FLATT, BRENTON T.; MARTIN, RICHARD; MOHAN, RAJU; MURPHY, BRETT

To: EXELIXIS, INC.

Reel/Frame 018405/0227 →